Allopurinol
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ALLOPURINOL |
|---|---|
| Type | Drug |
| Aliases | ZyloprimАлопуринол |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML DIS-CLL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Xanthine oxidase inhibitor |
|---|---|
| Mechanism | Inhibits xanthine oxidase, reducing uric acid production. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard TLS prophylaxis when initiating chemoimmunotherapy in patients with high tumor burden. Start 24-48 hours before therapy.
Used By
Indications
IND-EMERG-TLS-PROPHYLAXIS-RASBURICASE- IND-EMERG-TLS-PROPHYLAXIS-RASBURICASE
Regimens
REG-VENETOCLAX-OBINUTUZUMAB- Venetoclax + Obinutuzumab (VenO), 12 months fixed-duration (CLL14 schedule)REG-VENETOCLAX-RITUXIMAB- Venetoclax + Rituximab (VenR), 24-month fixed-duration (MURANO schedule)
Supportive Care
SUP-TLS-PROPHYLAXIS- Tumor lysis syndrome prophylaxis